LONDON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- According to The Business Research Company’s research report on the non-animal alternatives testing market, use of 3D-printed organs is an important trend in the non-animal alternatives testing market. 3D-printed organs involve a fusion between tissue engineering and 3D printing. The 3D-printing techniques are used to create tissue-like structures from biomaterials and cells which are then cultured in a microfluidic system. These have the potential to test drugs on human tissues grown in 3D structures bio printed with materials compatible with the in-vitro conditions. With these organs, the researchers can test drugs and therapies in the human body without animal testing. For instance, the Wake Forest Institute for Regenerative Medicine’s researchers constructed miniature lungs and colons using 3D printers to create pinhead-sized replicas of human organs to test drugs for COVID-19.
LAST TWO DAYS of TBRC’s huge market intelligence report sale! Grab your deal now.
The global non-animal alternatives testing market size is expected to grow from $1.63 billion in 2021 to $1.78 billion in 2022 at a compound annual growth rate (CAGR) of 9.08%. Non-animal alternatives testing market growth is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $2.59 billion in 2026 at a CAGR of 9.83%.
The global non-animal alternatives testing market is fragmented, with a large number of small players. The top ten competitors in the market made up to 7.90% of the total market in 2020. The market consolidation can be attributed to the partnerships and collaborations among the players in the industry to save costs, enhance their product offerings and expand geographically. The market is expected to be concentrated state in near future with the adoption of acquisition and merger strategies by the players to enter and expand into newer geographies. Major players in the non-animal alternatives testing are MatTek Corporation, Cyprotex, Emulate Inc, BioIVT, Bio-Rad Laboratories, GE Healthcare, SGS SA, BioIVT, Abbott Laboratories and Gentronix Limited.
The non-animal alternatives testing market is segmented by technology into cell culture technology, high throughput technology, molecular imaging, omics technology and other technologies; by method into cellular assay, biochemical assay, in silico, and ex-vivo; by end user into the pharmaceutical industry, cosmetics and household products, diagnostics, chemicals industry, food & beverage industry and other end users.
The use of human-patient simulators for testing is another major trend in the non-animal alternatives testing market. Such human-patient simulators are life-size adult and infant patient simulators that replicate elements of human physiology and can ‘breathe’, ‘talk’, ‘bleed’, ‘convulse’, and even ‘die’. They have been shown to be a more effective method of teaching students physiology and pharmacology compared with crude exercises that involve cutting up animals. Many medical schools across the USA, Canada, and India have replaced the use of animal laboratories with simulators as well as computer simulators, virtual reality systems, and supervised clinical experience in medical training. In January 2019, Simulab Launched new AirwayMan simulator, a new complete airway management training system to practice and train for complete airway management from nasal and oral intubation to needle and surgical cricothyroidotomy
North America was the largest region in the non-animal alternatives testing market, accounting for 42.7% of the total in 2020. It was followed by the Asia Pacific, Western Europe and then the other regions. Going forward, Middle East and Asia Pacific will be forerunners propelling the non-animal alternatives testing industry growth. These will be followed by Africa and Eastern Europe, where the markets are expected to register CAGRs of 8.6% and 8.4% respectively during 2020-2025.
Non-Animal Alternatives Testing Market Global Report 202 2 : Market Size, Trends, And Global Forecast 2022 - 2026 is one of a series of new reports from The Business Research Company that provide non-animal alternatives testing market overviews, non-animal alternatives testing market analyze and forecast market size and growth for the whole market, non-animal alternatives testing market segments and geographies, non-animal alternatives testing market trends, non-animal alternatives testing market drivers, non-animal alternatives testing market restraints, non-animal alternatives testing market leading competitors’ revenues, profiles and market shares in over 1,000 industry reports, covering over 2,500 market segments and 60 geographies.
The report also gives in-depth analysis of the impact of COVID-19 on the market. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. A highly experienced and expert team of analysts and modelers provides market analysis and forecasts. The reports identify top countries and segments for opportunities and strategies based on market trends and leading competitors’ approaches.
Not the market you are looking for? Check out some s imilar market intelligence reports :
Animal Testing And Non-Animal Alternative Testing Market - By End-Use (Pharmaceuticals, Academic Research, Medical Devices, Chemicals & Pesticides, Cosmetics), Drivers, Restraints, Opportunities And Strategies – Global Forecast To 2035
3D Bioprinting Global Market Report 2021 – By Component (3D Bioprinters, Bioinks ), By Material (Living Cells, Hydrogels, Extracellular Matrices), By Application (Research Applications, Clinical Application), By End User (Research Organization And Academic Institutes, Biopharmaceuticals Companies, Hospitals), COVID-19 Implications And Growth
3D Cell Culture Technologies Global Market Report 2021 - By Type (Scaffold-Based, Scaffold-Free, 3D Bioreactors), By End Users (Research Laboratories And Institutes, Biotechnology And Pharmaceutical Companies, Hospitals And Diagnostic Centers), By Scaffold-Based (Hydrogels, Polymeric Scaffolds, Micropatterned Surface Microplates), By Scaffold-Free (Hanging Drop Microplates, Spheroid Microplates, Microfluidic 3D Cell Culture, Magnetic Levitations & 3D Bioprinting), By Application (Cancer Research, Stem Cell Research, Drug Discovery, Regenerative Medicine), COVID-19 Growth And Change
Interested to know more about The Business Research Company?
The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.
The World’s Most Comprehensive Database
The Business Research Company’s flagship product, Global Market Model, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets which help its users assess supply-demand gaps.
The Business Research Company Europe: +44 207 1930 708 Asia: +91 8897263534 Americas: +1 315 623 0293 Email: firstname.lastname@example.org LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: http://blog.tbrc.info/